Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA055366 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA055366, RRID:AB_2682795
- Product name
- Anti-CLK2
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human CLK2, Gene description: CDC-like kinase 2, Alternative Gene Names: clk2, Validated applications: ICC, IHC, WB, Uniprot ID: P49760, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4
Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas
Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma
Tiek D, Wells C, Schröder M, Song X, Alamillo-Ferrer C, Goenka A, Iglesia R, Lu M, Hu B, Kwarcinski F, Sintha P, de Silva C, Hossain M, Picado A, Zuercher W, Zutshi R, Knapp S, Riggins R, Cheng S, Drewry D
Current Research in Chemical Biology 2023;3
Current Research in Chemical Biology 2023;3
Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas
Tiek D, Erdogdu B, Razaghi R, Jin L, Sadowski N, Alamillo-Ferrer C, Hogg J, Haddad B, Drewry D, Wells C, Pickett J, Song X, Goenka A, Hu B, Goldlust S, Zuercher W, Pertea M, Timp W, Cheng S, Riggins R
Science Advances 2022;8(25)
Science Advances 2022;8(25)
Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma
Park S, Piao Y, Thomas C, Fuller G, de Groot J
Oncotarget 2016;7(18):26793-26805
Oncotarget 2016;7(18):26793-26805
No comments: Submit comment
No validations: Submit validation data